‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight
Top Story
Archived
•
October 1, 2026
•
The drug, the first of its kind to target three metabolic receptors (GLP-1, GIP, and glucagon), is nearing the end of clinical trials and is expected to be submitted to the FDA for approval early next year.
Source: New York Post | https://nypost.com/feed/ - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



